Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
56.7 USD | -0.62% | +6.79% | -9.60% |
18/04 | Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating | MT |
17/04 | Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.60% | 4.84B | |
+20.23% | 46.81B | |
-0.99% | 41.37B | |
+47.53% | 41.29B | |
-6.20% | 28.87B | |
+11.21% | 26.06B | |
-19.75% | 19.13B | |
+32.21% | 12.39B | |
+0.28% | 12.08B | |
+0.30% | 11.96B |
- Stock Market
- Equities
- CRSP Stock
- News CRISPR Therapeutics AG
- Barclays Adjusts Price Target on Crispr Therapeutics to $148 from $160, Keeps Overweight Rating